Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 24.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 14.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of |
| 24.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 01.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 22.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | her securities of the Company. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 10.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 30.03.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | by specific reference in such filing. Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related |
Stammdaten
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Unternehmen & Branche
| Name | TALPHERA, INC. |
|---|---|
| Ticker | TLPH |
| CIK | 0001427925 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 16,4 Mio. USD |
| Beta | 0,56 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -14,290,000 | 29,719,000 | 17,035,000 | ||
| 2025-09-30 | 10-Q | -4,436,000 | 30,742,000 | 19,177,000 | ||
| 2025-06-30 | 10-Q | -3,489,000 | 16,515,000 | 6,627,000 | ||
| 2025-03-31 | 10-Q | -2,593,000 | -0.10 | 14,995,000 | 5,599,000 | |
| 2024-12-31 | 10-K | -13,004,000 | 18,236,000 | 8,001,000 | ||
| 2024-09-30 | 10-Q | -3,353,000 | 21,014,000 | 9,641,000 | ||
| 2024-06-30 | 10-Q | -3,827,000 | 24,856,000 | 12,730,000 | ||
| 2024-03-31 | 10-Q | -3,954,000 | -0.16 | 28,772,000 | 16,334,000 | |
| 2023-12-31 | 10-K | -18,397,000 | -1.29 | 20,395,000 | 14,105,000 | |
| 2023-09-30 | 10-Q | -1,357,000 | -0.08 | 23,261,000 | 18,307,000 | |
| 2023-06-30 | 10-Q | -4,371,000 | -0.40 | 17,725,000 | 10,419,000 | |
| 2023-03-31 | 10-Q | -8,152,000 | 26,292,000 | 14,242,000 | ||
| 2022-12-31 | 10-K | 47,755,000 | 5.72 | 47,487,000 | 21,814,000 | |
| 2022-09-30 | 10-Q | -6,750,000 | -0.94 | 48,310,000 | 27,226,000 | |
| 2022-09-30 | 10-K | 55,239,000 | 6.68 | |||
| 2022-06-30 | 10-Q | 70,663,000 | 8.58 | 56,133,000 | 33,143,000 | |
| 2022-06-30 | 10-K | 70,663,000 | 8.58 | |||
| 2022-03-31 | 10-Q | -8,674,000 | 71,971,000 | -38,273,000 | ||
| 2021-12-31 | 10-K | -35,099,000 | -5.86 | 77,893,000 | -35,893,000 | |
| 2021-09-30 | 10-Q | -8,375,000 | -1.40 | 72,263,000 | -43,021,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | Angotti Vincent J. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 105,364 | 0.81 | 85,587.18 | +191,3% | |
| 2026-02-12 | Aslam Shakil | Officer, Chief Medical Officer | Open Market Purchase | 35,000 | 0.81 | 28,430.50 | +63,5% | |
| 2026-02-12 | Dasu Badri N | Officer, Chief Engineering Officer | Open Market Purchase | 35,000 | 0.81 | 28,430.50 | +63,5% | |
| 2026-02-12 | ASADORIAN RAFFI | Officer, Chief Financial Officer | Open Market Purchase | 45,000 | 0.81 | 36,553.50 | +81,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.